The Association of Leukocyte Immunoglobulin-like Receptor B4 (LILRB-4) with Central Nervous System Involvement in Patients with Acute Myeloid Leukemia
The prevalence of central nervous system (CNS) involvement in patients with acute myeloid leukemia (AML) is variable with a reported range of 0.6% to 46%. Unfortunately, the clinical consequences of untreated CNS involvement in AML which include complete paraplegia and bilateral total blindness, can be devastating. In addition, both the diagnostic evaluation and treatment of CNS involvement are associated with potential significant morbidity. Thus, there is a need to predict CNS involvement in a noninvasive manner in patients with AML.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Colin Bergstrom, Weina Chen, Cheng Zhang, L.D. Anderson, Farrukh Awan, Steven Chung, Syed Rizvi, Praveen Ramakrishnan, Madhuri Vusirkala, Prapti Patel, Robert H. Collins, Ankit J. Kansagra Tags: 151 Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Blindness | Hematology | Leukemia | Opthalmology | Transplants